Allison J. Greaney

Allison J. Greaney

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Allison J. Greaney

Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Cell
Verified
Journal Article
Open access
TSTyler N. Starr
Tyler N. Starr
AGAllison J. Greaney
Allison J. Greaney
SHSarah K. Hilton
Sarah K. Hilton
DEDaniel Ellis
Daniel Ellis
KCKatharine Crawford
Katharine Crawford
JBJesse Bloom
Jesse Bloom
The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein mediates viral attachment to ACE2 receptor and is a major determinant of host range and a dominant target of neutralizing antibodies. Here, we experimentally measure how all amino acid mutations to the RBD affect expression of folded protein and its affinity for ACE2. Most mutations are deleterious for RBD expression and ACE2 binding, and we identify constrained regions on the RBD’s surface that may be desirable targets for vaccines and antibody-based therapeutics. But a substantial number of mutations are well tolerated or even enhance ACE2 binding, including at ACE2 interface residues that vary across SARS-related coronaviruses. However, we find no evidence that these ACE2-affinity-enhancing mutations have been selected in current SARS-CoV-2 pandemic isolates. We present an interactive visualization and open analysis pipeline to facilitate use of our dataset for vaccine design and functional annotation of mutations observed during viral surveillance.

19 February 2021 in Science
Verified
Journal Article
Open access
PDF file
TSTyler N. Starr
Tyler N. Starr
AGAllison J. Greaney
Allison J. Greaney
AAAmin Addetia
Amin Addetia
WHWilliam W. Hannon
William W. Hannon
MCManish Chandra Choudhary
Manish Chandra Choudhary
JBJesse Bloom
Jesse Bloom
Mapping antibody escape in SARS-CoV-2: Several antibodies are in use or under development as therapies to treat COVID-19. As new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants emerge, it is important to predict whether they will remain susceptible to antibody treatment. Starr et al. used a yeast library that covers all mutations to the SARS-CoV-2 receptor-binding domain that do not strongly disrupt binding to the host receptor (ACE2) and mapped how these mutations affect binding to three leading anti–SARS-CoV-2 antibodies. The maps identify mutations that escape antibody binding, including a single mutation that escapes both antibodies in the Regeneron antibody cocktail. Many of the mutations that escape single antibodies are circulating in the human population. Science , this issue p. 850

7 July 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
AGAllison J. Greaney
Allison J. Greaney
TSTyler N. Starr
Tyler N. Starr
CBChristopher O. Barnes
Christopher O. Barnes
YWYiska Weisblum
Yiska Weisblum
FSFabian Schmidt
Fabian Schmidt
JBJesse Bloom
Jesse Bloom
Monoclonal antibodies targeting a variety of epitopes have been isolated from individuals previously infected with SARS-CoV-2, but the relative contributions of these different antibody classes to the polyclonal response remains unclear. Here we use a yeast-display system to map all mutations to the viral spike receptor-binding domain (RBD) that escape binding by representatives of three potently neutralizing classes of anti-RBD antibodies with high-resolution structures. We compare the antibody-escape maps to similar maps for convalescent polyclonal plasmas, including plasmas from individuals from whom some of the antibodies were isolated. While the binding of polyclonal plasma antibodies are affected by mutations across multiple RBD epitopes, the plasma-escape maps most resemble those of a single class of antibodies that target an epitope on the RBD that includes site E484. Therefore, although the human immune system can produce antibodies that target diverse RBD epitopes, in practice the polyclonal response to infection is skewed towards a single class of antibodies targeting an epitope that is already undergoing rapid evolution.

1 April 2021 in Cell Reports Medicine
Verified
Journal Article
Open access
TSTyler N. Starr
Tyler N. Starr
AGAllison J. Greaney
Allison J. Greaney
ADAdam Dingens
Adam Dingens
JBJesse Bloom
Jesse Bloom
Monoclonal antibodies and antibody cocktails are a promising therapeutic and prophylaxis for coronavirus disease 2019 (COVID-19). However, ongoing evolution of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can render monoclonal antibodies ineffective. Here, we completely map all of the mutations to the SARS-CoV-2 spike receptor-binding domain (RBD) that escape binding by a leading monoclonal antibody, LY-CoV555, and its cocktail combination with LY-CoV016. Individual mutations that escape binding by each antibody are combined in the circulating B.1.351 and P.1 SARS-CoV-2 lineages (E484K escapes LY-CoV555, K417N/T escapes LY-CoV016). In addition, the L452R mutation in the B.1.429 lineage escapes LY-CoV555. Furthermore, we identify single amino acid changes that escape the combined LY-CoV555+LY-CoV016 cocktail. We suggest that future efforts diversify the epitopes targeted by antibodies and antibody cocktails to make them more resilient to the antigenic evolution of SARS-CoV-2.

22 July 2022 in Science
Verified
Journal Article
Open access
TSTyler N. Starr
Tyler N. Starr
AGAllison J. Greaney
Allison J. Greaney
WHWilliam W. Hannon
William W. Hannon
ALAndrea Loes
Andrea Loes
KHKevin Hauser
Kevin Hauser
JBJesse Bloom
Jesse Bloom
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved variants with substitutions in the spike receptor-binding domain (RBD) that affect its affinity for angiotensin-converting enzyme 2 (ACE2) receptor and recognition by antibodies. These substitutions could also shape future evolution by modulating the effects of mutations at other sites—a phenomenon called epistasis. To investigate this possibility, we performed deep mutational scans to measure the effects on ACE2 binding of all single–amino acid mutations in the Wuhan-Hu-1, Alpha, Beta, Delta, and Eta variant RBDs. Some substitutions, most prominently Asn 501 →Tyr (N501Y), cause epistatic shifts in the effects of mutations at other sites. These epistatic shifts shape subsequent evolutionary change—for example, enabling many of the antibody-escape substitutions in the Omicron RBD. These epistatic shifts occur despite high conservation of the overall RBD structure. Our data shed light on RBD sequence-function relationships and facilitate interpretation of ongoing SARS-CoV-2 evolution.

5 August 2022 in Science
Verified
Journal Article
Open access
ACAlexander A. Cohen
Alexander A. Cohen
NDNeeltje van Doremalen
Neeltje van Doremalen
AGAllison J. Greaney
Allison J. Greaney
HEHanne Andersen Andersen Elyard
Hanne Andersen Andersen Elyard
ASAnkur Sharma
Ankur Sharma
Pamela J BjorkmanPamela J Bjorkman
Pamela J Bjorkman
To combat future severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and spillovers of SARS-like betacoronaviruses (sarbecoviruses) threatening global health, we designed mosaic nanoparticles that present randomly arranged sarbecovirus spike receptor-binding domains (RBDs) to elicit antibodies against epitopes that are conserved and relatively occluded rather than variable, immunodominant, and exposed. We compared immune responses elicited by mosaic-8 (SARS-CoV-2 and seven animal sarbecoviruses) and homotypic (only SARS-CoV-2) RBD nanoparticles in mice and macaques and observed stronger responses elicited by mosaic-8 to mismatched (not on nanoparticles) strains, including SARS-CoV and animal sarbecoviruses. Mosaic-8 immunization showed equivalent neutralization of SARS-CoV-2 variants, including Omicrons, and protected from SARS-CoV-2 and SARS-CoV challenges, whereas homotypic SARS-CoV-2 immunization protected only from SARS-CoV-2 challenge. Epitope mapping demonstrated increased targeting of conserved epitopes after mosaic-8 immunization. Together, these results suggest that mosaic-8 RBD nanoparticles could protect against SARS-CoV-2 variants and future sarbecovirus spillovers.